본문바로가기

Who We Are

Wellmarker Bio Co., Ltd.(WMBIO) Develops Anticancer Drugs Based on Predictive Biomarkers for Unmet Medical Needs

Wellmarker Bio is a spin-off company from Seoul Asan Medical Center (AMC), which is the largest and most renowned hospital in the Republic of Korea. We specialize in developing predictive biomarkers and first-in-class drugs through profound research know-hows and clinical information from AMC. We strive to bring a better outcome to patients and contribute to the healthy life of a mankind through ‘New Drug Development Research Institute’ that is comprised of bio-research center, medicinal chemistry research center, cmc center and clinical development center.

Areas of Expertise

Our Key Areas of Expertise are Predictive Biomarker Development and Drug Discovery Including Small Molecules and Biologics

We are developing predictive biomarkers and anticancer drugs for solid tumors by utilizing in-house research facilities and clinical information from AMC.

On many occasions, “new drug development” can be said to be a “comprehensive art.” To perform this “comprehensive art”, it requires an amazing storyline, stage setting, and above all, a great actor. In the same way, WMBIO continues to make ceaseless effort on developing new drugs by working together with global partners. We will continue to strive in contributing to the healthy life of mankind.

Company History

2016

12 Company Founded

2017

04 R&D Center Established

05 Pipeline WM-S1(Small Molecule, Colon Cancer)
Has Been Selected by KDDF
* KDDF: Korea Drug Development Fund

07 Acquired the Venture Business Certification

10 Research Collaboration Agreement with Y-Biologics

2018

02 Pipeline WM-A1(Therapeutic Antibody, Lung Cancer) Has Been Selected by KDDF

10 Completed Series A($28million)

2019

02 MOU Signed with KIRAMS
(Korea Institute for Radiological and Medical Sciences)

03 MOU Signed with Ukrainian National Medical Institutions (VNMU/PRCO)

03 Pipeline WM-S1 Has Been Selected as
a KDDF Follow-up Project

06 MOU Signed with Cytogen for
Companion Diagnostics

07 Signed Technology Transfer Contract with KIRAMS(L/I)

07 Completed Series B($18million)

10 MOU Signed with Azothbio

10 Received the Grand Prize at the
‘2019 5th Korean Good Company Awards’ in Bio Sector

2020

03Research Collaboration Agreement with AzothBio on AI-based Anticancer Drug Development

05Branch Research Center(CMC Center) Established

05‘Startup Scale-Up Package’ Program Selected by MSS
* MSS: Ministry of SMEs and Startups

10Received the Grand Prize at the ‘2020 6thKorean Good Company Awards’ in Bio Sector for 2 Consecutive Years

CI Guideline

The Company Logo of WMBIO Embodies
the Corporate Value of Pursing a Happy Future and a Healthy Life of Mankind

A balanced, solid and stable hexagonal frame represents the best global biotechnology company with experienced researchers and technology. It implicitly visualizes fruit and lantern that lights up the future through innovation, determination, and strong leadership in bio industry.

Organizational Structure

Collaborations

Wellmarker Bio is Committed to Developing New Drugs through
Continuous Cooperation with Global Partners